1. Lee, F. Y.; Lien, J. C.; Huang, L. J.; Huang, T. M.; Tsai, S. C.; Teng, C. M.; Wu, C. C.; Cheng, F. C.; Kuo, S. C. Synthesis of 1-Benzyl-3-(5-hydroxymethyl-2-furyl)-
indazole Analogues as Novel Antiplatelet Agents. J. Med. Chem. 2001, 44, 3746–
3749.
2. Wu, C. C.; Huang, S. W.; Hwang, T. L.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YD-3, a novel inhibitor of protease-induced platelet activation. Br. J. Pharmacol. 2000, 130, 1289–1296.
3. Wu, C. C.; Hwang, T. L.; Liao, C. H.; Kuo, S. C.; Lee, F. Y.; Lee, C. Y.; Teng, C. M. Selective Inhibition of Protease-activated Receptor 4-dependent Platelet Activation by YD-3. Thromb. Haemost. 2002, 87, 1026–1033.
4. Wu, C. C.; Hwang, T. L.; Liao, C. H.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb. Haemost. 2003, 90, 299–308.
5. L. C. Behr, Indazoles and condensed types. In A. Weissberger Ed.︰The chemistry of heterocyclic compounds: Pyrazoles, pyrazolines, pyrazolidines, indazoles and condensed rings. 1967; Pt. 3, pp 289–382.
6. Gladstone, W. A. F.; Norman, R. O. C. Reactions of lead tetra-acetate. Part II. A new synthesis of 1-arylindazoles. J. Chem. Soc. 1965, 3048–3050.
7. Yoshina, S.; Tanaka, A.; Kuo, S. C. Studies on heterocyclic compounds. XXXIII. Synthesis of furo[3,2-c]pyrazole derivatives. (1). Synthetic investigation of furo
[3,2-c]pyrazoles (author''s transl). Yakugaku Zasshi 1977, 97, 955–961.
8. Lee, K. Y.; Kim, J. M.; Kim, J. N. Regioselective synthesis of 1,3,4,5-tetra
substituted pyrazoles from Baylis–Hillman adducts. Tetrahedron Lett. 2003, 44, 6737–6740.
9. Lee, K. Y.; Gowrisankar, S.; Kim, J. N. Facile synthesis of 2H-indazole derivatives starting from the Baylis–Hillman adducts of 2-cyclohexen-1-one. Tetrahedron Lett. 2005, 46, 5387–5391.
10. Angelis, M. D.; Stossi, F.; Carlson, K. A.; Katzenellenbogen, B. S.; Katzenellen-
bogen, J. A. Indazole Estrogens: Highly Selective Ligands for the Estrogen Receptor β. J. Med. Chem. 2005, 48, 1132–1144.
11. Hannig, E.; Kollmorgen, C.; Geipel, I. The preparation of some derivatives of 5-methylindazole-3-carboxylic acid. Pharmazie 1973, 28, 720–723.
12. Hannig, E.; Kollmorgen, C.; Dressel, M. Various derivatives of 1-benzyl-6-
aminoindazole. Pharmazie 1974, 29, 685–687.
13. Ina, S.; Inoue, S.; Noguchi, I. N-heterocyclic compounds. I. Facile synthesis of 5,6-dialkoxy-2-aryl-2H-indazoles (author''s transl). Yakugaku Zasshi 1975, 95, 1245–
1249.
14. Corsi, G.; Palazzo, G. 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents. J. Med. Chem. 1976, 19, 778–783.
15. Bistocchi, G. A.; Meo, G. D.; Pedini, M.; Ricci, A.; Brouilhet, H.; Boucherie, S.; Rabaud, M.; Jacquignon, P. N1-substituted 1H-indazole-3-ethyl carboxylates and 1H-indazole-3-hydroxamic acids. Farmaco, Edizione Scientifica 1981, 36, 315–333.
16. Conway, G. A.; Loeffler, L. J.; Hall, I. H. Synthesis and antitumor evaluation of selected 5,6-disubstituted 1(2)H-indazole-4,7-diones. J. Med. Chem. 1983, 26, 876–
884.
17. Cecchi, L.; Melani, F.; Filacchioni, G.; Tredici, M. Synthesis and biological activity of some 3-(pyrazol-1''-yl)indazole derivatives. Farmaco, Edizione Scientifica 1984, 39, 945–952.
18. Mosti, L.; Menozzi, G.; Schenone, P.; Molinario, L.; Conte, F.; Montanario, C.; Marmoe, E. Acetic acids bearing the 1-phenyl-1H-indazole nucleus with analgesic and anti-inflammatory activity. Farmaco, Edizione Scientifica 1988, 43, 763–774.
19. Mosti, L.; Menozzi, G.; Schenone, P.; Cervo, D.; Esposito, G.; Marmoe, E. 4-Substituted 1-phenyl-1H-indazoles with analgesic, anti-inflammatory, antipyretic and local anesthetic activities. Farmaco 1990, 45, 415–429.
20. Robertson, D. W.; Bloomquist, W.; Cohen, M. L.; Reid, L. R.; Schenck, K.; Wong, D. T. Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-
8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxamide, a useful radioligand for 5HT3 receptors.J. Med. Chem. 1990, 33, 3176–3181.
21. Wrzeciono, U.; Linkowska, E.; Majewska, K.; Gzella, A.; Stochla, K. Synthesis and anti-inflammatory activity of some indazole derivatives. 36. Azoles. Pharmazie 1993, 48, 582–584.
22. Perni, R. B.; Wentland, M. P.; Huang, J. I.; Powles, R. G.; Aldous, S.; Klingbeil, K. M.; Peverly, A. D.; Robinson, R. G.; Corbett, T. H.; Jones, J. L.; Mattes, K. C.; Rake, J. B.; Coughlin, S. A. Synthesis and Antitumor Activity of 4-Aminomethylthio-
xanthenone and 5-Aminomethylbenzothiopyranoindazole Derivatives. J. Med. Chem. 1998, 41, 3645–3654.
23. Andronati, S.; Sava, V.; Makan, S.; Kolodeev, G. Synthesis of 3-aryl-1-[(4-
phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors. Pharmazie 1999, 54, 99–101.
24. Song, J. J.; Yee, N. K. A novel synthesis of 2-aryl-2H-indazoles via a palladium-
catalyzed intramolecular amination reaction. Org. Lett. 2000, 2, 519–521.
25. Isin, E. M.; Jonge, M. D.; Castagnoli, N. J. Studies on synthetic approaches to 1H- and 2H-indazolyl Derivatives. J. Org. Chem. 2001, 66, 4220–4226.
26. Hayes, B. L. In Microwave synthesis–Chemistry at the speed of light. 2002, pp 14–18.
27. Varma, R. S.; Dahiya, R. Sodium borohydride on wet clay: Solvent-free reductive amination of carbonyl compounds using microwaves. Tetrahedron 1998, 54, 6293–
6298.
28. Chandrasekhar, S.; Takhi, M.; Uma, G. Solvent-free N-alkyl and N-arylimides preparation from anhydrides catalyzed by TaCl5-silica gel. Tetrahedron Lett. 1997, 38, 8089–8092.
29. Baumgartner, H. P.; Muggli, R.; Tschopp, T. B.; Turitto, V. T. Platelet adhesion, release and aggregation in flowing blood︰effects of surface properties and platelet function. Thromb. Haemost. 1976, 35, 124–138.
30. Stemerman, M. B.; Baumgartner, H. R.; Spaet, T. H. The subendothelial microfibril and platelet adhesion. Lab. Invest. 1972, 24, 176–186.
31. Malmsten, C.; Hamberg, M.; Svensson, J.; Samuelsson, B. Physiological role of an endoperoxide in human platelets: hemostatic defect due to cyclooxygenase deficiency. Pro. Natl. Acad. Sci. 1975, 72, 1446–1448.
32. http://www.biocarta.com/pathfiles/h_Par1Pathway.asp.
33. https://oa.doria.fi/dspace/bitstream/10024/1257/1/activati.pdf.
34. Coller, B. S. Antiplatelet agents in the prevention and therapy of thrombosis. Annu. Rev. Med. 1992, 43, 1171–1180.
35. http://www.molcar.med.kyushu-u.ac.jp/study14.html.
36. Festoff, B. W.; Smirnova, I. V.; Ma, J.; Citron, B. A. Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Semin. Thromb. Hemost. 1996, 22, 267–271.
37. Macfarlane, S. R.; Seatter, M. J.; Kanke, T. G.; Hunter, D.; Plevin, R. Proteinase-
activated receptors. Pharmacol. Rev. 2001, 53, 245–282.
38. Carmeliet, P. Clotting factors build blood vessels. Science 2001, 293, 1602–1604.
39. Kahn, M. L.; Nakanishi-Matsui, M.; Shapiro, M. J.; Ishihara, H. Coughlin, S. R. Protein Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 1999, 103, 879–887.
40. Dery, O.; Corvera, C. U.; Steinhoff, M.; Bunnett, N. W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am. J. Physiol. 1998, 274, 1429–1452.
41. Cupit, L. D.; Schmidt, V. A.; Bahou, W. F. Proteolytically activated receptor-3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets. Trends Cardiovasc. Med. 1999, 9, 42–48.
42. Kahn, M. L.; Zheng, Y. W.; Huang, W.; Bigornia, V.; Zeng, D.; Moff, S.; Farese, R. V.; Jr; Tam, C.; Coughlin, S. R. Nucleotide, OMIM, Protein A dual thrombin receptor system for platelet activation. Nature 1998, 394, 690–694.
43. Xu, W. F.; Andersen, H.; Whitmore, T. E.; Presnell, S. R.; Yee, D. P.; Ching, A. Gilbert, T.; Davie, E. W.; Foster, D. C. Nucleotide, OMIM, Free in PMC , Protein Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. 1998, 95, 6642–6646.
44. D''Andrea, M. R.; Saban, M. R.; Nguyen, Ngoc-Bich; Andrade-Gordon, P.; Saban, R. Expression of Protease-Activated Receptor-1, -2, -3, and -4 in Control and Experimentally Inflamed Mouse Bladder. Am. J. Pathol. 2003, 162, 907–923.
45. http://www.sigma-aldrich.com/ehandbook. pp 210, 211.
46. Seiler, S. M. Thrombin receptor antagonists. Semin. Thromb. Hemost. 1996, 22, 223–232.
47. Zhang, H. C.; Derian, C. K.; Andrade-Gordon, P.; Hoekstra, W. J.; McComsey, D. F.; White, K. B.; Poulter, B. L.; Addo, M. F.; Cheung, W. M.; Damiano, B. P.; Oksenberg, D.; Reynolds, E. E.; Pandey, A.; Scarborough, R. M.; Maryanoff, B. E. Discovery and Optimization of a Novel Series of Thrombin Receptor (PAR-1) Antagonists: Potent, Selective Peptide Mimetics Based on Indole and Indazole Templates. J. Med. Chem. 2001, 44, 1021–1024.
48. McEver, R. P. Leukocyte interactions mediated by selectins. Thromb. Haemost. 1991, 66, 80–87.
49. Semenov A. V.; Romanov Y. A.; Loktionova S. A. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry Moso. 1999, 64, 1326–
1335.
50. http://www.p.bunri-u.ac.jp/lab/akagi/akagi.gif.
51. http://www.rosaceatoday.com/images/chrt_InflammatoryMediators.jpg.
52. Harman, D.; Piette, L. H. Free radical theory of aging: free radical reactions in serum. J. Gerontol. 1966, 21, 560–565.
53. Parks, D. A.; Granger, D. N. Ischemia induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am. J. Physiol. 1983, 245, G285–G289.
54. McCord, J. M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 1985, 312, 159–163.
55. Kvietys, P. R.; Smith, S. M.; Grisham, M. B.; Manaci, E. A. 5-Aminosalicylic acid protects against ischemia/reperfusion-induced gastric bleeding in the rat. Gastroenterology 1988, 94, 733–738.
56. McCord, J. M. Free radicals and inflammation: protection of synovial fluid by superoxide dismutase. Science 1974, 185, 529–531.
57. Allen, R. E.; Blake, D. R.; Nazhat, N. B.; Jones, P. Superoxide radical generation by inflammed human synovium after hypoxia. Lancet. 1989, 2, 282–283.
58. Craven, P. A.; Pfanstiel, J.; Saito, R.; DeRubertis, F. R. Action of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology 1987, 92, 1998–2008.
59. Grisham, M. B.; Granger, D. N. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig. Dis. Sci. 1988, 33 (3 Suppl), 6S–15S.
60. Weissmann, G.; Smolen, J. E.; Korchak, H. M. Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 1980, 303, 27–34.
61. Davies, M.; Barrett, A. J.; Travis, J.; Sanders, E.; Coles, G. A. The degradation of human glomerular basement membrane with purified lysosomal proteinases: evidence for the pathogenetic role of the polymorphonuclear leukocyte in glomerulonephritis. Clin. Sci. Mol. Med. 1978, 54, 233–240.
62. Menninger, H.; Putzier, R.; Mohr, W.; Weissinghage, D.; Tillmann, K. Granulocyte elastase at the site of cartilage erosion by rheumatoid synovial tissue. J. Rheumatol. 1980, 39, 145–156.
63. Saklatvala, J.; Barrett, A. J. Identification of proteinases in rheumatoid synovium: detection of leukocyte elastase, cathepsin G and another serine proteinase. Biochem. Biophys. Acta. 1980, 615, 167–177.
64. Kunkel, S. L.; Chensue, S. W.; Phan, S. H. Prostaglandins as endogenous mediators of interleukin 1 production. J. Immunol. 1986, 136, 186–192.
65. Nathan, C. F. Secretory products of macrophages. J. Clin. Invest. 1987, 79, 319–326.
66. Beutler, B.; Cerami, A. Tumor necrosis factor, cachexia, shock, and inflammation: a commom mediator. Ann. Rev. Biochem. 1988, 57, 505–518.
67. Ding, A. H.; Nathan, C. F.; Stuehr, D. J. Release of reactive nitrogen inter-
mediates and reactive oxygen intermediates from mouse peritonel macrophages: comparison of activiting cytokines and evidence for independent production. J. Immunol. 1988, 141, 2407–2412.
68. Shaw, C. A.; Taylor, E. L.; Megson, I. L.; Rossi, A. G. Nitric oxide and the resolution of inflammation: implications for atherosclerosis. Mem. Inst. Oswaldo. Cruz. 2005, 100 (Suppl. I Rio de Janeiro), 67–71.
69. Tracey, K. J.; Fong, Y.; Hesse, D. G.; Manogue, K. R.; Lee, A. T.; Kuo, G. C.; Lowry, S. F.; Cerami, A. Anti-cachectin/TNF monoclonal antibodies prevent septic sock during lethal bacteraemia. Nature 1987, 330, 662–664.
70. Yan, S. D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A. M. RAGE and amyloid-B peptide neurotoxicity in Alzheimer′s disease. Nature 1996, 382, 685–691.
71. Mallat, M.; Chamak, B. Brain macrophages: neurotoxic or neurotrophic effector cells. J. Leukoc. Biol. 1994, 56, 416–422.
72. Gehrmann, J.; Matsumoto, Y.; Kreutzberg, G. W. Microglia: intrinsic immuno effector cell of the brain. Brain. Res. Rev. 1995, 20, 269–287.
73. Hofman, F. M.; Hinton, D. R.; Johnson, K.; Merrill, J. E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 1989, 170, 607–612.
74. Rogers, J.; Luber-Narod, J.; Styren, S. D.; Civin, W. H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer''s disease. Neurobiol. Aging. 1988, 9, 339–349.
75. McGeer, P. L.; Itagaki, S.; Boyes, B. E.; McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson''s and Alzheimer''s disease brains. Neurology 1988, 38, 1285–1291.
76. Dickson, D. W.; Mattiace, L. A.; Kure, K.; Hutchins, K.; Lyman, W. D.; Brosnan, C. F. Microglia in human disease, with an emphasis on acquired immune deficiency syndrome. Lab. Invest. 1991, 64, 135–156.
77. Gebicke-Haerter, P. J.; Bauer, J.; Schobert, A.; Northoff, H. Lipopolysaccharide free conditions in primary astrocyte cultures allow growth and isolation of microglia cells. J. Neurosci. 1989, 9, 183–194.
78. Minghetti, L.; Nicolini, A.; Polazzi, E.; Crfiinon, C.; Maclouf, J.; Levi, G. Inducible nitric oxide synthase exoression in activated rat microglial cultures is down -regulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1991, 19, 152–160.
79. Chao, C. C.; Hu, S.; Molitor, T. W.; Shaskanand, E. G.; Peterson, P. K. Activated microglia mediate neuronal cell death injury via a nitric oxide mechanism. J. Immunol. 1992, 149, 2736–2741.
80. Merrill, J. E.; Ignarro, L. J.; Sherman, M. P.; Melinek, J.; Lane, T. E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 1993, 151, 2132–2141.
81. Meda, L.; Cassatella, M. A.; Szendrei, G. I.; Otvos, L. Jr.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995, 374, 647–650.
82. Ko, F. N.; Wu, C. C.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84, 4226–4233.
83. Wu, C. C.; Ko, F. N.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 1995, 116, 1973–1978.
84. Huang, L. J.; Shih, M. L.; Chen, H. S.; Pan, S. L.; Teng, C. M.; Lee, F. Y.; Kuo, S. C. Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-
angiogenic agents. Bioorg. Med. Chem. 2006, 14, 528–536.
85. Tietze, L. F.; Beifuss, U. In: Trost, B. M.; Fleming, I. Ed. Comprehensive Organic Synthesis. 1991; Vol. 2, Pergamon Press, Oxford, pp 341–394.
86.李芳裕，3-(5''-羥甲基-2''-呋喃基)-1-苯甲基吲唑類緣化合物之合成及其抗血小板活性，私立中國醫藥學院藥物化學研究所博士論文，1997。87.石美玲，1(或2)-(取代苄基)-3-(4-甲基苯基)-1(或2)氫-吲唑類化合物之合成及其抗血小板、抗血管增生與細胞致毒活性，私立中國醫藥學院藥物化學研究所碩士論文，2002。88. Stork, G.; Terrell, R.; Szmuszkovicz, J. A new synthesis of 2-alkyl and 2-acyl ketones. J. Am. Chem. Soc. 1954, 76, 2029–2030.
89. McCrae, W. In Basic Organic Reaction; Heyden & Son: New York, 1973, pp 80–
82.
90. Norman, R. In Organic Synthesis, 2nd ed.; John Wiley & Sons: New York, 1967; Col. Vol. 4. pp 536–539.
91. Richard, H. W. In Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings; Interscience: New York, 1967; Pt. 3, pp 289–382.
92.陳華鑫，4-(1-苄基-1H-吲唑-3-基)苯甲酸乙酯(YD-3)類緣化合物之合成與抗血小板活性，私立中國醫藥學院藥物化學研究所碩士論文，2002。93.蔡勝忠，YC-1之苯并咪唑類緣化合物的合成及其抗血小板凝集活性，私立中國醫藥學院藥物化學研究所博士論文，2000。94. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. In Spectrometric Identification of Organic Compounds, 5th ed.; John Wiley & Sons, Inc., 1991.
95. Fresenius, W.; Huber, J. F. K.; Pungor, E.; Rechnitz, G. A.; Simon, W.; West, T. S. In Tables of Spectral Data for Structure Determination of Organic Compounds, 2nd.; Springer-Verlag, 1989.
96. Fernandez, P. A.; Bellamy, T.; Kling, M.; Madge, D. J.; Selwood, D. L. A convenient route to the solubkle guanylate cyclase activator YC-1 and its N2 regioisomer. Heterocycles 2001, 55, 1813–1816.
97.蔡睿盈，1-苄基-3-(5-取代-2-呋喃基)-5-甲氧基-1H-吲唑衍生物之合成及其抗血小板、抗血管增生與細胞致毒活性，私立中國醫藥學院藥物化學研究所碩士論文，2003。98.郭瓊文，N1-和N2-苄基-3-(3-取代苯基)吲唑類衍生物之合成及其生物活性，中國醫藥大學藥學院藥物化學研究所碩士論文，2006。99.李宇鈞，4-(1-苯基-1H-吲唑-3-基)苯甲酸乙酯類緣化合物之合成與抗血小板活性，私立中國醫藥學院藥物化學研究所碩士論文，2002。100. Markert, M.; Andrews P. C. Measurement of O2-production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Meth. Enzymol. 1984, 105, 358–365.
101. Newby, A. C. Role of adenosine deaminase, ecto-(5''-nucleotidase) and ecto-
(non-specific phosphatase) in cyanide-induced adenosine monophosphate catabolism in rat polymorphonuclear leucocytes. Biochem. J. 1980, 186, 907–918.
102. Absolom, D. R. Basic methods for the study of phagocytosis. Meth. Enzymol. 1986, 132, 95–180.
103. Barrett, A. J. In Lysosomes, 2nd.; Amsterdam, Elsevier, 1972, pp118–120.
104. Wang, J. P.; Raung, S. L.; Hsu, M. F.; Lin, C. C. Inhibition by gomisin C (a lignan from Schizandra chinensis) of the respiratory burst of rat neutrophils. Br. J. Pharmacol. 1994, 113, 945–953.
105. Goldberg, B.; Stem, A. The role of the superoxide anion as a toxic species in the erythrocyte. Arch. Biochem. Biophys. 1977, 178, 218–225.
106. Corradin, S. B.; Manuel, J.; Donini, S. D.; Quattrocchi, E.; Ricciardi-Castagnoi, P. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia. 1993, 7, 255–262.
107. Minghetti, L.; Nicolini, A.; Polazzi, E.; Creminon, C.; Maclouf, J.; Levi, G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997, 19, 152–160.
108. McClain, D. E.; Donlon, M. A.; Chock, S.; Catravas, G. N. The effect of calmodulin on histamine release in the rat peritoneal mast cell. Biochem. Biophys. Acta. 1983, 763, 419–425.
109. Wang, J. P.; Hsu, M. F.; Raung, S. L.; Kuo, S. C. Suppressive effect of 2-phenyl-4-quinolone (YT 1) on hind-paw edema and cutaneous vascular plasma extravasation in mice. Naunyn-Schmiedeberg''s Archives of Pharmacology 1994, 349, 324–330.
110. Johnson, A. R.; Erdos, E. G. Release of histamine from mast cells by vasoactive peptides. Proc. Soc. Exp. Biol. Med. 1973, 142, 1252–1256.
111. Hakanson, R.; Ronnberg, A. L. Improved fluorometric assay of histamine. Antlyt. Biochem. 1974, 60, 560–567.